22 / 28
Page 57
conferenceseries
.com
Volume 08
Journal of Alzheimers Disease & Parkinsonism
Alzheimer's Congress 2018
May 30-31, 2018
May 30-31, 2018 Osaka, Japan
10
th
World Congress on
Alzheimer's Disease & Dementia
Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of alzheimer’s disease
Meiling Ge
Sichuan University, China
Introduction & Purpose:
Alzheimer’s Disease (AD) is a globally prevalent neurodegenerative disease, clinically characterized by
progressive memory loss and gradual impairment of cognitive functions. Mesenchymal Stem Cells (MSCs) transplantation has
been considered a possible therapeutic method for AD. However, no quantitative data synthesis of MSCs therapy for AD exists.
We conducted a systematic review and meta-analysis to study the effects of MSCs on cognitive deficits in animal models of AD.
Method:
We identified eligible studies published from January 1980 to January 2017 by searching four electronic databases
(PubMed, Medline, Embase, CNKI). The endpoint was the effects of MSCs on cognitive performance evaluated by the Morris
Water Maze (MWM) test including escape latency and the number of platform crossing and time in the target quadrant.
Result:
Nine preclinical studies incorporating 225 animals with AD were included for the meta-analysis. The studies indicated
that MSCs based treatment significantly improved the learning function through measurements of the escape latency (SMD=-
0.99; 95% CI=-1.33 to -0.64; P<0.00001). Additionally, we observed that transplantation of MSCs significantly increased
the number of platform crossing in six experiments (SMD=0.78; 95% CI=0.43 to 1.13; P<0.0001). What’s more, the times
in the target quadrant were increased in five studies indicated that transplantation of MSCs could ameliorate the cognitive
impairments (SMD=1.06; 95% CI=0.46 to 1.67; P=0.0005).
Conclusion:
The current study showed that MSCs transplantation could reduce cognitive deficits in ADmodels. These findings
support the further studies to translate MSCs in the treatment of AD in humans.
gemeiling025@163.comJ Alzheimers Dis Parkinsonism 2018, Volume 8
DOI: 10.4172/2161-0460-C4-046